Boston Scientific Acquires Valencia Technologies to Enhance Urology Portfolio and OAB Solutions
- Boston Scientific acquires Valencia Technologies to enhance its urology offerings for overactive bladder treatment.
- The eCoin® System, an FDA-approved device, significantly improves urge urinary incontinence in patients not responding to traditional treatments.
- This acquisition strengthens Boston Scientific's urology market position and commitment to innovative solutions for bladder dysfunction.
Boston Scientific Expands Urology Portfolio with Acquisition of Valencia Technologies
Boston Scientific Corporation, a prominent player in the medical technology industry, announces its definitive agreement to acquire Valencia Technologies Corporation, a privately held firm specializing in solutions for bladder dysfunction. This strategic move, aimed at enhancing Boston Scientific's urology offerings, centers on addressing the pressing needs of the approximately 30 million adults aged 40 and older in the United States who suffer from overactive bladder (OAB). The agreement, made public on January 12, 2026, represents a significant step in Boston Scientific’s mission to deliver innovative and effective treatment options for urological conditions.
Valencia Technologies is renowned for its eCoin® System, an FDA-approved implantable tibial nerve stimulation (ITNS) device designed to alleviate urge urinary incontinence (UUI), a common symptom of OAB. The eCoin device, roughly the size of a coin, is implanted subcutaneously near the ankle and is particularly beneficial for patients who have not responded to conventional treatment methods. Clinical trials demonstrate promising results, with 68% of participants experiencing at least a 50% reduction in UUI episodes following implantation. This impressive efficacy underscores the potential for the eCoin device to significantly improve the quality of life for millions of patients grappling with this condition.
Meghan Scanlon, senior vice president and president of Urology at Boston Scientific, emphasizes that the acquisition will enhance the company's ITNS capabilities, complementing its existing pelvic health product line. This expansion not only broadens the range of treatment options available but also aligns with Boston Scientific's commitment to fostering innovative solutions that address patient needs. The acquisition is anticipated to close in the first half of 2026, pending standard conditions, and while it may slightly impact adjusted earnings per share, the company expects a greater dilution on a GAAP basis due to related costs. Specific financial details of the transaction remain undisclosed.
In addition to enhancing its product offerings, Boston Scientific’s acquisition of Valencia Technologies reflects a strategic focus on expanding its reach within the urology sector. The company has been a leader in medical technology for over 45 years, continually prioritizing innovative solutions that improve patient health and help reduce healthcare costs. This acquisition aligns with Boston Scientific's vision of providing comprehensive care for those suffering from complex medical conditions.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

